{"id":30420,"date":"2017-03-22T17:16:49","date_gmt":"2017-03-22T16:16:49","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=30420"},"modified":"2017-03-22T17:16:49","modified_gmt":"2017-03-22T16:16:49","slug":"spagna-antitrust-avviato-un-procedimento-disciplinare-6-aziende-farmaceutiche","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/spagna-antitrust-avviato-un-procedimento-disciplinare-6-aziende-farmaceutiche\/","title":{"rendered":"Spain. Antitrust has initiated disciplinary proceedings against 6 pharmaceutical companies"},"content":{"rendered":"<p>The National Commission for the Market and Competition (CNMC) <b>initiated disciplinary proceedings against Pfizer, Janssen-Cilag, Merck Sharp &amp; Dohme Spain, Lilly, Sanofi-Aventis, Novartis<\/b>\u00a0for alleged anti-competitive behavior. According to the Commission i<span class=\"goog-text-highlight\">the crime they would have committed would be\u00a0<\/span><span class=\"goog-text-highlight\">the establishment of a distribution system <img decoding=\"async\" class=\"alignright\" src=\"http:\/\/www.zonamovilidad.es\/fotos\/2\/cnmc-p.jpg\" alt=\"Risultati immagini per Comisi\u00f3n Nacional de los Mercados y la Competencia CNMC\" \/>through which they would be implemented or would stand <\/span><span class=\"goog-text-highlight\">For <\/span><span class=\"goog-text-highlight\">implement a dual price display system, such as <\/span><span class=\"goog-text-highlight\">as well as a collusive agreement between the companies to design and implement these distribution systems.<\/span><\/p>\n<p>The Commissioners analyzed the conduct arising from a complaint filed by the European Association of Euro Pharmaceutical Companies (EAEPC) in 2007 against the above companies. <span class=\"goog-text-highlight\">In 2009, the National Competition Commission (CNC) <\/span><b><span class=\"goog-text-highlight\">decided not to <\/span><span class=\"goog-text-highlight\">initiate disciplinary proceedings<\/span><\/b><span class=\"goog-text-highlight\"> and order the archiving of the behaviors followed, considering that in fact it has not been demonstrated\u00a0<\/span><b><span class=\"goog-text-highlight\">no evidence of forgery.<\/span><\/b><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/publicaciones.adicae.net\/publicaciones\/fototeca\/cnmc.jpg\" alt=\"Risultati immagini per Comisi\u00f3n Nacional de los Mercados y la Competencia CNMC\" width=\"298\" height=\"149\" \/>Subsequently, the Supreme Court (in its judgment of March 4, 2016), reversed the decision in which this matter was dismissed, and urged the CNMC to continue its actions in relation to these facts.<\/p>\n<p>According to a note released by the Competition, the initiation of these proceedings does not prejudge the final outcome of the investigation. Now CNMC has a maximum period of 18 months to investigate the case and resolve it.<\/p>\n<div class=\"info\">\n<div class=\"byline\"><a href=\"http:\/\/www.elglobal.net\/industria-farmaceutica\/competencia-inicia-expediente-sancionador-contra-seis-laboratorios-MH810439\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\"><b>EL GLOBAL\u00a0<\/b>Madrid | Mar 21, 2017<\/span><\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>La Commissione Nazionale per il Mercato e la Concorrenza (CNMC) ha avviato un procedimento disciplinare contro Pfizer, Janssen-Cilag, Merck Sharp &amp; Dohme Spagna, Lilly, Sanofi-Aventis, Novartis\u00a0per presunti comportamenti anticoncorrenziali. Secondo la Commissione il reato che avrebbero commesso sarebbe\u00a0l&#8217;istituzione di un sistema di distribuzione attraverso il quale avrebbero attuate o starebbe per implementare un sistema di &hellip;<\/p>","protected":false},"author":4,"featured_media":30422,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[22],"class_list":["post-30420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-truffa-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/30420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=30420"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/30420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/30422"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=30420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=30420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=30420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}